Basel Medical Group Ltd

Basel Medical Group Ltd(BMGL)股票分析

$5.190

0.000 (0.00%)收盤時

Loading chart…
最高
5.300
開盤
5.200
成交量加權均價
5.21
成交量
2.40M
市值
—
最低
5.125
成交金額
12.49M
企業價值/稅息折舊攤銷前利潤(TTM)
0.00

Basel Medical Group Ltd is a holding company, which operates through its subsidiary, Basel Medical Group Pte. Ltd. It provides a wide spectrum of general and subspecialized orthopedic, trauma and sports medicine services such as knee/hip replacements, sports medicine/surgery, spine surgery, foot/ankle surgery and minimally invasive orthopedic procedures, as well as neurosurgical treatments. Its orthopedic treatments and surgery include non-surgical treatments, such as medications, injections, splinting and physiotherapy, and surgical orthopedic procedures, including minimally invasive treatments for complex surgeries. Its rehabilitative therapy provides in-house physiotherapy treatments, including post-surgery rehabilitation, as well as sports therapy. Its neurosurgical care covers treatments involving spinal and brain conditions, from headaches and brain tumors to spinal issues, aneurysms and strokes. It also specializes in diagnostic imaging and outpatient care.

AI 分析 of Basel Medical Group Ltd (BMGL)

買進

Basel Medical Group Ltd (BMGL) appears to be a good buy right now, as it has shown a strong recent performance with a 5-day change of +12.31% and a 20-day change of +61.20%. The stock is currently priced at $5.11, which is significantly below its 52-week high of $18.72, indicating potential for recovery. Additionally, the RSI is at 92.981, suggesting that the stock is in a strong upward momentum. However, investors should be cautious of the high debt-to-equity ratio of 137.69%, which poses a risk to financial stability.

估值指標

Basel Medical Group Ltd(BMGL)目前預期本益比為 0.00,5 年平均預期本益比為 0.00。

預期本益比

嚴重低估
5 年均值 P/E
0.00
目前P/E
0.00
高估
0.00
低估
0.00

預期 EV/EBITDA

嚴重低估
5 年均值 EV/EBITDA
0.00
目前EV/EBITDA
0.00
高估
0.00
低估
0.00

預期股價營收比

嚴重低估
5 年均值 P/S
0.00
目前P/S
0.00
高估
0.00
低估
0.00

Alphio AI 對 BMGL 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%BMGL

$2.44

情境價格

基

基準

基準 · 50%BMGL

$2.17

情境價格

悲

悲觀

悲觀 · 25%BMGL

$2.01

情境價格

事件時間軸

2026-10-08 (ET)

13:30:00

Basel Medical Group Issues 6 Million Units at $1.33 Each

2026-09-16 (ET)

11:30:00

Basel Medical Group Ltd Trading Halted Due to Volatility

2026-09-15 (ET)

16:00:00

Basel Medical Group Ltd Trading Halted

2026-07-02 (ET)

14:00:00

Basel Medical Group Ltd Trading Halted

2026-03-24 (ET)

06:40:00

Basel Medical Complies with Nasdaq Periodic Filing Requirements

資訊

BMGL 常見問題 —— 由 Alphio AI 解答

Basel Medical Group Ltd is a holding company, which operates through its subsidiary, Basel Medical Group Pte. Ltd. It provides a wide spectrum of general and subspecialized orthopedic, trauma and sports medicine services such as knee/hip replacements, sports medicine/surgery, spine surgery, foot/ankle surgery and minimally invasive orthopedic procedures, as well as neurosurgical treatments. Its orthopedic treatments and surgery include non-surgical treatments, such as medications, injections, splinting and physiotherapy, and surgical orthopedic procedures, including minimally invasive treatments for complex surgeries. Its rehabilitative therapy provides in-house physiotherapy treatments, including post-surgery rehabilitation, as well as sports therapy. Its neurosurgical care covers treatments involving spinal and brain conditions, from headaches and brain tumors to spinal issues, aneurysms and strokes. It also specializes in diagnostic imaging and outpatient care. It operates in the Healthcare sector.

Basel Medical Group Ltd (BMGL) appears to be a good buy right now, as it has shown a strong recent performance with a 5-day change of +12.31% and a 20-day change of +61.20%. The stock is currently priced at $5.11, which is significantly below its 52-week high of $18.72, indicating potential for recovery. Additionally, the RSI is at 92.981, suggesting that the stock is in a strong upward momentum. However, investors should be cautious of the high debt-to-equity ratio of 137.69%, which poses a risk to financial stability.

暫無貼文

註冊或登入後參與討論

相關文章

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易